Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Articles|October 18, 2022
Rheumatoid Arthritis Quiz: Race and Multimorbidity
Author(s)Ingrid Torjesen
People with rheumatoid arthritis are also more likely to live with other chronic conditions, but specific ones vary by race. Test your knowledge of how race affects multimorbidity in this quiz.
Advertisement
Is the following statement true or false?
People with rheumatoid arthritis have a twofold greater odds of multimorbidity than people without rheumatoid arthritis, regardless of their race and ethnicity.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement